ACR 2022 Tweet by Aurelie Najm

Tweet
Aurelie Najm @AurelieRheumo Nov 12, 2022
View on
RECITAL trial: First line RTX vs. CYC in ILD 🫁 asso w/ SSc, mixed CTD or Myositis.
Primart endpoint FVC 24 wks improved in both mCTD and Myositis associated ILD but only stabilized in SSc-ILD. RTX improved skin thickness 24 wks. t.co/MQcqds0jYA
Abst#0003 #ACR22 @Rheumnow
Rituximab versus Cyclophosphamide for the Treatment of Connective Tissue Disease Associated Interstitial Lung Disease (RECITAL): A Sub-group Analysis of a Multi-centre Randomised Controlled Trial - ACR Meeting Abstracts
Image from Aurelie Najm’s tweet

Related Content

Article Education/ACR/EULAR

Best of 2025: ERS/EULAR guidelines for CTD-related interstitial lung disease

Jack Cush, MD Dec 31, 2025
The European Respiratory Society (ERS) and European Alliance of Associations for Rheumatology (EULAR) have published clinical practice guidelines for the evaluation and management of connective tissue diseases (CTD) associated interstitial lung disease (ILD) in two simultaneous publications in the European Respiratory Journal and Annals of Rheumatic Diseases.
Article Education/ACR/EULAR

EBR Journal Club: Brepocitinib in Dermatomyositis (VALOR)

Michael Putman, MD, MSCI Oct 6, 2026
The EBR Journal Club Companion applies my adapted version of the JAMA approach to critical appraisal. Each review covers four domains: Does this apply to my patients? What is the risk of bias? How great are the benefits and harms? And what didn’t they show me? Feel free to use this in your own journal clubs! This edition: VALOR (brepocitinib in dermatomyositis).
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

Topics

×